Mesoblast is a biotechnology business based in Australia. Mesoblast shares (MSB) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Mesoblast has a trailing 12-month revenue of around $7.5 million. If you're looking to buy shares, check out the steps below.
Our top pick for
Low costs
Our top pick for
Education & learning
Our top pick for
Australian stocks
| 52-week range | $0.34 - $1.425 |
|---|---|
| 50-day moving average | $0.3725 |
| 200-day moving average | $0.7873 |
| Target price | $0.69 |
| PE ratio | 0 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.18 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.405
| 1 week (2023-11-23) | 2.53% |
|---|---|
| 1 month (2023-11-03) | 9.46% |
| 3 months (2023-09-01) | -11.96% |
| 6 months (2023-06-02) | -61.97% |
| 1 year (2022-12-02) | -63.35% |
|---|---|
| 2 years (2021-12-03) | -73.95% |
| 3 years (2020-12-03) | -90.49% |
| 5 years (2018-12-03) | -69.55% |
| Revenue TTM | $7.5 million |
|---|---|
| Gross profit TTM | $-47,421,000 |
| Return on assets TTM | -6.51% |
| Return on equity TTM | -16.4% |
| Profit margin | 0% |
| Book value | 0.617 |
| Market capitalisation | $321.6 million |
TTM: trailing 12 months
We're not expecting Mesoblast to pay a dividend over the next 12 months.
Mesoblast's shares were split on a 299:296 basis on 29 August 2017. So if you had owned 296 shares the day before the split, the next day you would own 299 shares. This wouldn't directly have changed the overall worth of your Mesoblast shares – just the quantity. However, indirectly, the new 1% lower share price could have impacted the market appetite for Mesoblast shares which in turn could have impacted Mesoblast's share price.
Over the last 12 months, Mesoblast's shares have ranged in value from as little as $0.34 up to $1.425. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Mesoblast's is 2.595. This would suggest that Mesoblast's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Looking to jump on the AI bandwagon? Here's how you can invest in ChatGPT and its parent company OpenAI from Australia.
Looking for the best performing stocks in Australia? We update this list weekly.
If you’re looking for ways to gain exposure to Bitcoin and other digital currencies, cryptocurrency ETFs could be worth exploring. Find out what crypto ETFs are and how they work in this introductory guide.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Steps to owning and managing Microsoft shares from in Australia.
Looking for alternative investments? With a ROI of up to 3,593% lego may be worth considering. Read on to find out which lego sets are worth the investment.
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
Learn about the money market and everyday consumer money market products.
Equity crowdfunding offers a unique opportunity for investors and for Australian startups, but Australia’s regulatory framework surrounding crowdfunding still lags behind the rest of the world.
Follow these tips to find the best share trading platform for you.
